Durvalumab in Combination with Olaparib in Non-Small Cell Lung Cancer

Durvalumab 联合奥拉帕尼治疗非小细胞肺癌

• 批准号: 10702748
• 负责人: Arun Rajan
• 金额: $ 9.93万
• 依托单位: DIVISION OF BASIC SCIENCES - NCI
• 依托单位国家: 美国
• 资助国家: 美国
• 起止时间: 至
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/10702748
• 关键词: Clinical; Complement; DNA Damage; Enrollment; Evaluable Disease; Immune checkpoint inhibitor; Immunotherapy; Measures; Monoclonal Antibodies; Non-Small-Cell Lung Carcinoma; PARP inhibition; Patients; Progression-Free Survivals; Recurrence; design; inhibitor; partial response; phase II trial; programmed cell death ligand 1; response; tumor

Study hypothesis: increased DNA damage by PARP inhibition will complement the anti-tumor activity of the immune checkpoint inhibitor, durvalumab. Study status: 18 patients with recurrent NSCLC have been enrolled, including patients previously treated with immunotherapy. Sixteen patients are evaluable for response. Two partial responses have been observed. The study is designed to enroll 20 patients initially. If after interim analysis, the median PFS is 3.5 months or less, the study will close to accrual. If PFS is greater than 3.5 months, accrual will continue until 37 patients are enrolled.

研究假设：通过PARP抑制增加的DNA损伤将补充免疫检查点抑制剂杜瓦卢马布的抗肿瘤活性。研究状态：已招募了18例复发性NSCLC患者，包括先前接受过免疫疗法治疗的患者。有16名患者可以评估以进行反应。已经观察到了两个部分反应。该研究最初旨在注册20名患者。如果经过临时分析后，中位PFS为3.5个月或更短，则该研究将接近应计。如果PFS大于3.5个月，则应计入37例患者。